Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

NCT00274456 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

302

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: ABI-007
DRUG: Docetaxel

Sponsor

Celgene